These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26641474)

  • 1. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
    Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
    Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
    Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ
    J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Sato Y; Yamamoto N; Kunitoh H; Ohe Y; Minami H; Laird NM; Katori N; Saito Y; Ohnami S; Sakamoto H; Sawada J; Saijo N; Yoshida T; Tamura T
    J Thorac Oncol; 2011 Jan; 6(1):132-8. PubMed ID: 21079520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
    Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
    BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
    Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
    J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
    Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F; Fenton D; Hirsh V; Zukin M; Stockler MR; Lee CW; Chen EX; Montenegro A; Ding K; Bradbury PA
    Eur J Cancer; 2014 Mar; 50(4):706-12. PubMed ID: 24360368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
    Crawford J; Swanson P; Schwarzenberger P; Sandler A; Prager D; Zhang K; Freeman DJ; Johnson CW; Krishnan K; Johnson D
    J Thorac Oncol; 2013 Dec; 8(12):1510-8. PubMed ID: 24389433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
    Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
    J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.